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cardial secretome has been de-
termined by quantitative MS-
based proteomics of mouse
embryonic endocardial cells
(MEEC). DLL4-mediated NOTCH
activation lead to expression of
EMT, cytoskeleton and cell-cell/
cell-matrix proteins, whereas
JAG1-NOTCH signaling acti-
vated ECM molecules expres-
sion. Data validation in vitro and
in vivo support the value of
MEEC as a model for studying
the endocardial secretome and
for the identification of novel fac-




• MEEC are a reliable endocardial in vitro model.
• Quantitative proteomics to characterize the NOTCH-driven endocardial secretome.
• NOTCH pathway status underlies different paracrine biological functions.
• New insights into secreted factors involved in cardiac valve development.
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NOTCH Activation Promotes Valve Formation
by Regulating the Endocardial Secretome*□S
Rebeca Torregrosa-Carrión‡§, Luis Luna-Zurita‡§, Fernando García-Marqués¶,
Gaetano D’Amato‡, Rebeca Piñeiro-Sabarís‡§, Elena Bonzón-Kulichenko§**,
Jesús Vázquez§**, and José Luis de la Pompa‡§‡‡
The endocardium is a specialized endothelium that lines
the inner surface of the heart. Functional studies in mice
and zebrafish have established that the endocardium is a
source of instructive signals for the development of car-
diac structures, including the heart valves and chambers.
Here, we characterized the NOTCH-dependent endocar-
dial secretome by manipulating NOTCH activity in mouse
embryonic endocardial cells (MEEC) followed by mass
spectrometry-based proteomics. We profiled different
sets of soluble factors whose secretion not only responds
to NOTCH activation but also shows differential ligand
specificity, suggesting that ligand-specific inputs may
regulate the expression of secreted proteins involved in
different cardiac development processes. NOTCH signal-
ing activation correlates with a transforming growth fac-
tor-2 (TGF2)-rich secretome and the delivery of para-
crine signals involved in focal adhesion and extracellular
matrix (ECM) deposition and remodeling. In contrast,
NOTCH inhibition is accompanied by the up-regulation of
specific semaphorins that may modulate cell migration.
The secretome protein expression data showed a good
correlation with gene profiling of RNA expression in em-
bryonic endocardial cells. Additional characterization by
in situ hybridization in mouse embryos revealed expres-
sion of various NOTCH candidate effector genes (Tgf2,
Loxl2, Ptx3, Timp3, Fbln2, and Dcn) in heart valve endo-
cardium and/or mesenchyme. Validating these results,
mice with conditional Dll4 or Jag1 loss-of-function muta-
tions showed gene expression alterations similar to those
observed at the protein level in vitro. These results pro-
vide the first description of the NOTCH-dependent endo-
cardial secretome and validate MEEC as a tool for assay-
ing the endocardial secretome response to a variety of
stimuli and the potential use of this system for drug
screening. Molecular & Cellular Proteomics 18: 1782–
1795, 2019. DOI: 10.1074/mcp.RA119.001492.
Signaling interactions are crucial during the various stages
of vertebrate cardiac development, from heart mesoderm
specification and migration through heart tube formation and
looping to the development, morphogenesis, and maturation
of the heart valves and chambers. The early heart tube is
formed by an outer epithelial myocardium and an inner endo-
cardial layer separated by an extracellular matrix, the cardiac
jelly. Inductive signaling between these two cell layers is cru-
cial for the development of specialized heart structures, such
as the valves and chambers.
During the formation of the heart valves, myocardium-de-
rived BMP2 (1, 2) and endocardium-derived NOTCH signals
(3), active in the prospective valve territory of the atrio-ven-
tricular canal (AVC) region, function in concert to induce the
epithelial-mesenchyme transition (EMT) of AVC endocardial
cells (4, 5). Transformed mesenchyme cells lose cell-cell junc-
tions, migrate, and colonize the AVC cardiac jelly to form the
endocardial cushions, which will later protrude into the heart
tube and function as primitive heart valves. Later, these mes-
enchymal cells proliferate and remodel by condensation and
elongation, to give rise to the delicate valve leaflets and sep-
tum of the mature heart (6).
NOTCH is a conserved family of single-pass transmem-
brane receptors that are activated by membrane-bound li-
gands of the DELTA (DLL1, DLL3, and DLL4) and JAGGED/
SERRATE (JAG1 and JAG2) families. Ligand-receptor
interaction leads to a series of proteolytic processing events
in the receptor that ultimately result in the generation of the
NOTCH intracellular domain, which translocate to the cell
nucleus and binds to a preexisting transcriptional complex to
regulate target gene expression (7). The many roles of NOTCH
in mammalian heart development include cardiac fate speci-
fication (8), heart tube patterning, and morphogenesis of car-
diac structures; moreover, NOTCH signaling alterations leads
to cardiac disease in humans (9). A key feature of NOTCH
function in the heart is that it exerts non-cell autonomous
effects on neighboring tissues. This is exemplified by the
effect of endocardial NOTCH activity on myocardial pattern-
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ing, presumably because NOTCH is required for the produc-
tion of endocardial signals acting on the myocardium (4,
10–13). Candidate signaling molecules have been identified
by gene expression profiling of NOTCH loss- or gain-of-
function models (4, 10, 12, 13), but so far, there has been a
lack of experimental models suitable for the proteomic iden-
tification of secreted endocardial proteins involved in car-
diac development.
Here, we used mouse embryonic endocardial cells (MEEC)
as an in vitro system to identify the NOTCH-dependent em-
bryonic endocardial secretome. MEEC were stimulated with
recombinant DLL4 and JAG1 in the presence or absence of
NOTCH inhibitors, and multiplexed quantitative proteomics
analysis of conditioned media identified proteins whose se-
cretion responds to NOTCH signaling manipulation. This anal-
ysis identified 875 secreted factors, 129 of which showed
significant expression changes after NOTCH manipulation;
moreover, we validated the protein expression data through
comparison with qRT-PCR and RNA profiling results from
MEEC. NOTCH activation correlated directly with increased
secretion of extracellular matrix (ECM) remodeling and struc-
tural proteins (TGF2 and collagens) and inversely with mol-
ecules involved in cellular migration/chemotaxis and protein-
modifying enzymes. Specifically, DLL4-NOTCH signaling
showed a major contribution to EMT, cytoskeleton signaling,
and cell-cell/cell-matrix contacts, whereas JAG1-NOTCH sig-
naling revealed a greater involvement in ECM deposition.
Validation by in situ hybridization revealed specific valve en-
docardium and mesenchyme expression of selected candi-
date molecules in wild-type mouse embryos and their altered
expression in NOTCH mutants. These findings coincide with
the early role described for DLL4-NOTCH1 signaling in the
promotion of EMT and cell migration and with a later role for
JAG1-NOTCH1 in the regulation of valve mesenchyme prolif-
eration and remodeling (13). These results affirm the value of
MEEC as a powerful in vitro model for studying the endocar-
dial secretome and identify novel factors potentially involved
in heart valve development and disease.
EXPERIMENTAL PROCEDURES
Isolation and Immortalization of MEEC—MEEC were obtained and
immortalized as described in (10).
Cell Culture—MEEC were cultured on 0.1% gelatin-coated 10-cm
dishes and maintained in Dulbecco’s modified Eagle’s medium
(DMEM) (Gibco) supplemented with 10% fetal bovine serum (FBS)
and 1% penicillin/streptomycin. Human umbilical vein endothelial
cells were purchased from Lonza, and cultured on 0.1% gelatin-
coated 10-cm dishes in Endothelial Cell Growth Medium-2 (EGM-2)
with supplements (Lonza) and 1% penicillin/streptomycin. Mouse
embryonic fibroblasts were obtained from E9.5 embryos disaggre-
gated with a 1-ml syringe plunger and were plated in DMEM with high
glucose and L-glutamine (Gibco), 15% FBS, 1 mM sodium pyruvate
(Sigma-Aldrich), 0.1 mM -mercaptoethanol (Sigma-Aldrich), and 1%
penicillin/ampicillin. All cell lines were incubated at 37 °C in a humid-
ified atmosphere containing 5% CO2.
Calcium Ionophore Treatment—MEEC cultured on 0.1% gelatin-
coated glass coverslips were exposed to 1 M A23187 calcium iono-
phore (#C5149 Sigma-Aldrich) or DMSO (vehicle) (Sigma-Aldrich) for
6 h at 37 °C prior to fixation.
Immunocytochemistry—Confluent cells cultured on 0.1% gelatin-
coated glass coverslips were fixed in 4% paraformaldehyde for 10
min at room temperature. MEEC were incubated with primary anti-
bodies for 1 h at room temperature, followed by incubation for 1 h
with a fluorescent-dye-conjugated secondary antibody. Antibodies
used in this study were as follows: anti-ERG (Abcam EPR3863, 1:100);
Alexa Fluor-488 conjugated goat anti-rabbit IgG (HL) (Thermo-
Fisher A-11034, 1:200); anti-NFATc1 (7A6; Enzo ALX-804-022-R100,
1:100); and goat anti-Mouse IgG (HL) Alexa Fluor-488 conjugate
(ThermoFisher A-11029, 1:100). Alexa Fluor-488-conjugated Isolectin
GS-IB4 from Griffonia simplicifolia (ThermoFisher I32450, 1:200) was
incubated for 4 min at room temperature prior to fixation. Fluorescein
isothiocyanate-labeled phalloidin (Sigma-Aldrich P5282 1:200) was
used to label actin filaments. Images were obtained with a NIKON
A1R confocal fluorescence microscope and an Olympus BX51 fluo-
rescence microscope.
Matrigel-based Tube Formation Assay—Each well of a 24-well
plate was coated with 300 l Growth Factor Reduced Matrigel (BD
Biosciences 354230) at 4 °C, and the Matrigel was allowed to polym-
erize at 37 °C for 30 min. MEEC were treated with VEGF (R&D Sys-
tems 293-VE, 20 ng/ml) for 1 week, and 5  104 or 7.5  104 cells per
well were added in DMEM and incubated for 6 h at 37 °C. Tube-like
structures were observed with the Nikon Eclipse TS100 Inverted
Microscope and photographed using the Nikon Digital Sight DS-
2MBWc camera. Each condition was tested in duplicate.
NOTCH Stimulation with Recombinant Ligands—Recombinant
NOTCH ligands DLL4-His (R&D Systems 1389-D4-050) and JAG1-Fc
(R&D Systems 599-JG-100) were attached to 10-cm dishes as de-
scribed in (14). MEEC (2.9  106 cells/plate) were seeded in DMEM
supplemented with 10% FBS and treated with 20 M of the -secre-
tase inhibitor RO4929097 (Selleck Chemicals S1575): to inhibit
NOTCH signaling, or DMSO (vehicle) for 24 h at 37 °C. The cells were
washed twice with PBS and incubated for an additional 14 h in
serum-free DMEM together with RO4929097 or DMSO as appropri-
ate. Each condition was performed in triplicate.
Quantitative RT-PCR—RNA from MEEC stimulated with NOTCH
recombinant ligands was extracted using the Direct-zol RNA Miniprep
Kit (Zymo Research). cDNA was synthesized using the High Capacity
Reverse Transcription Kit (Applied Biosystems), with 1 g total RNA
per reaction. Quantitative PCR was performed using Power SYBRTM
Green Master Mix (Applied Biosystems 4367659) with the 7900HT
Fast Real-Time PCR System (Applied Biosystems). Relative expres-
sion was determined using Gapdh or -Actin as housekeeping genes.
Mouse KiCqStartTM primer sequences (Sigma-Aldrich) used in this
study are listed in Table S8. Three technical experiments were per-
formed in each biological triplicate. Data are presented as mean 
s.d. Differences were considered statistically significant at p  0.05
(two-tailed Student’s t test).
Collection of Conditioned Media—Conditioned media from conflu-
ent serum-starved MEEC was collected by gentle aspiration and
1 The abbreviations used are: AVC, atrio-ventricular canal; BMP2,
bone morphogenetic protein 2; ECM, extracellular matrix; EMT, epi-
thelial-mesenchymal transition; ERG, ets-related gene; FASP, filter
aided sample preparation; HCD, higher-energy collisional dissocia-
tion; HUVEC, human umbilical vein endothelial cells; KEGG, kyoto
encyclopedia of genes and genomes; LC-MS proteomics, Liquid
Chromatography Mass Spectrometry proteomics; MECC, mouse em-
bryonic endocardial cells; PCA, principal component analysis;
TGF2, transforming growth factor beta 2; WSPP, weighted spec-
trum, peptide and protein.
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centrifuged at 1200 rpm for 5 min to remove cell debris. The clear
supernatant was immediately frozen in liquid nitrogen and then stored
at 80 °C until proteomic analysis.
Experimental Design and Statistical Rationale—MEEC were stimu-
lated with DLL4 or JAG1 in the presence of DMSO (vehicle) or
RO4929097, and only DMSO represented the control condition (Fig.
1A). Conditioned media from these five experimental conditions were
analyzed in biological triplicates in two independent tandem mass tag
(TMT) 10-plex experiments (Fig. S2A). One TMT was used to study
stimulation by DLL4 and the other to study stimulation by JAG1. Each
TMT contained 3 controls (in DMSO, which were the same in both
TMT experiments); 3 samples with the corresponding NOTCH ligand;
3 samples with the corresponding NOTCH ligand and RO4929097;
and a common pool of all 15 samples was used as an internal control
(Fig. S2A). The three biological replicates of each condition showed
reproducible changes and clustered together into the same groups
(see, for instance, Fig. 2A). Quantitative information from TMT re-
porter intensities was integrated from the spectrum level (Table S1), to
the peptide level, and then to the protein level based on the weighted
spectrum, peptide and protein (WSPP) statistical model (15, 16) using
the generic integration algorithm (17). Briefly, for each sample r, the
values xqps  log2 Ai/C were calculated, where Ai is the intensity of the
TMT reporter of the corresponding sample i in the MS/MS spectrum
s coming from peptide p and protein q, and C is the intensity of the
TMT reporter from the internal control. The log2-ratio of each peptide
(xqp) was calculated as the weighted mean of its spectra, the protein
values (xq) were the weighted mean of its peptides, and the grand
mean (x) was calculated as the weighted mean of all the protein values
(15). The statistical weights of spectra, peptides, and proteins (wqps,




2 , respectively), were calculated as described
(15). Protein abundance changes are expressed in standardized units
(zq). Built-in routines from the SanXoT package (18) were used to
confirm that the z_q variables from each one of the samples followed
strict normal N (0, 1) distributions, as expected from the WSPP model
(17). Significant protein abundance changes across the different sam-
ples were detected by applying Student’s t test to zq data, and
differences were considered statistically significant at p  0.05.
LC-MS Proteomics—Proteins from the conditioned media were
digested overnight at 37 °C in filter aided sample preparation filters
with trypsin (Promega, Madison, WI, USA) at a 40:1 protein:trypsin
(w/w) ratio in 50 mM ammonium bicarbonate, pH 8.8. The resulting
peptides were desalted with C18 Oasis cartridges (Waters Corpora-
tion, Milford, MA, USA), using 50% acetonitrile (v/v) in 0.1% trifluo-
roacetic acid (v/v) as eluent, and vacuum-dried. The peptides were
TMT labeled following manufacturer’s instructions. Labeled peptides
from each TMT experiment were pooled, separated into six fractions
by mixed-cation exchange chromatography (Oasis HLB-MCX col-
umns), desalted, and analyzed using a Proxeon Easy nano-flow HPLC
system (Thermo Fisher Scientific, Bremen, Germany) coupled via a
nanoelectrospray ion source (Thermo Fisher Scientific) to an Orbitrap
Fusion mass spectrometer (Thermo Fisher Scientific). C18-based re-
verse-phase separation was used with a 2-cm trap column and a
50-cm analytical column (EASY column, Thermo Fisher Scientific) in a
continuous acetonitrile gradient consisting of 0–30% A for 180 min,
50–90% B for 3 min (A  0.1% formic acid; B  90% acetonitrile,
0.1% formic acid) at a flow rate of 200 nl/min. Mass spectra were
acquired in a data-dependent manner, with an automatic switch
between MS and MS/MS using a top 15 method. MS spectra in the
Orbitrap analyzer were in a mass range of 400–1500 m/z and 120,000
resolution. Higher-energy collisional dissociation fragmentation was
performed at 35 eV of normalized collision energy and MS/MS spec-
tra were analyzed at 30,000 resolution in the Orbitrap.
All searches were performed with Proteome Discoverer (version
1.4, Thermo Fisher Scientific) using SEQUEST (Thermo Fisher Scien-
tific) against an Uniprot database containing all sequences from
mouse (December 2015; 16,747 entries) and supplemented with 116
sequences from the cRAP database, containing the most common
laboratory protein contaminants (Global Proteome Machine). For da-
tabase searching, parameters were selected as follows: trypsin di-
gestion with two maximum missed cleavage sites, precursor mass
tolerance of 2 Da, fragment mass tolerance of 30 ppm. Methionine
oxidation (15.994915) was set as a variable modification. Lysine and
peptide N-terminal modification of 229.162932 Da, as well as cys-
teine carbamidomethylation of 57.021464 Da, were set as fixed
modifications. The same MS/MS spectra collections were also
searched against inverted databases constructed from the same
target databases. Peptide identification from MS/MS data was per-
formed using the probability ratio method (19). False discovery rates
of peptide identifications were calculated using the refined method
(20, 21) a 1% false discovery rate was used as the peptide identifi-
cation criterion. Each peptide was assigned only to the best protein
proposed by the Proteome Discoverer algorithm. The whole set of
identified peptides and proteins is shown in Table S1.
Bioinformatic Filtering of Secretory Proteins—The computational
prediction of protein secretion was done as in (22) and is shown in
Fig. 1D and Table S2. Briefly, from all the identified proteins at false
discovery rate 1%, a list of potentially secreted proteins that met
at least one of the following three criteria was constructed: (1)
proteins annotated as extracellular by the DAVID v.6.7 website for
Gene Ontology (GO) localization; (2) from the list of proteins not
fulfilling the criteria in (1), proteins containing more than two trans-
membrane helices predicted by the TMHMM v.2.0 server (23), and
a signal peptide according to the SignalP v.4.1 server. Those were
termed as potentially secreted via the classical pathway; (3) pro-
teins not fulfilling the criteria in (2) that had a SecretomeP v.2.0
score 0.5. Proteins in category (2) were classified as potentially
secreted via the classical pathway; proteins in category (3) were
classified as potentially secreted by a nonclassical pathway (24). To
prevent overlap among secretion criteria, proteins were listed only
under one category.
Data Representation—Principal component analysis was per-
formed using ClustVis (https://biit.cs.ut.ee/clustvis/) (25) on the 690
secreted proteins common to the DLL4- and JAG1-specific datasets.
Heatmaps were generated in ClustVis. Volcano plots were repre-
sented using a python custom script with the Matplotlib library, and
protein names were added manually.
GO and KEGG Pathway Enrichment Analysis—GO and Kyoto en-
cyclopedia of genes and genomes (KEGG) Pathway enrichment analy-
ses of differentially secreted proteins were performed in GO-Elite
(www.genmapp.org/go_elite/; 1.2.5, EnsMart77Plus database version)
(26) with a permuted p value cutoff p  0.05. We used the set of 690
proteins identified in both mixes as background, except for the network
analysis, where we used the NOTCH-dependent endocardial secre-
tome (129 differentially secreted proteins). Bar charts representing the
z-score values of the terms in each category (biological process, cellular
component, molecular function, and KEGG pathways) were generated
with GraphPad Prism 7.
Network Analysis of Proteomic Data—The 129 differentially se-
creted proteins showing differential regulation after global NOTCH
pathway activation/inhibition, served as input node data for the
STRING 11.0 database (http://string-db.org/) (27). To obtain more
stringent interactions, the Textmining option in STRING was ex-
cluded, and the minimum required interaction score considered was
0.7 (high confidence). Resulting networks were then replotted using
Cytoscape 3.7.1 (www.cytoscape.org/) (28), by applying the Prefuse
NOTCH Regulates the Endocardial Secretome
1784 Molecular & Cellular Proteomics 18.9
Force Directed Layout setting for the global analysis. The significance
of the predicted network was assayed using as background the set of
690 proteins identified in both mixes.
Tissue Processing and In Situ Hybridization (ISH)—Embryos were
fixed in 4% paraformaldehyde at 4 °C overnight. Embryos older than
E10.5 were paraffin embedded following standard protocols. ISH and
whole-mount ISH were performed as described (29, 30). Details of
probes will be provided on request.
Mouse Strains and Genotyping—Animal studies were approved by
the CNIC Animal Experimentation Ethics Committee and by the Com-
munity of Madrid (Ref. PROEX 118/15). All animal procedures con-
formed to EU Directive 2010/63EU and Recommendation 2007/
526/EC regarding the protection of animals used for experimental and
other scientific purposes, enforced in Spanish law under Real Decreto
1201/2005. Mouse strains used in this study were Tie2-Cre (31),
Nkx2.5-Cre (32), Dll4flox (33), and Jag1flox (34). Details of genotyping
have been published for Dll4flox;Tie2-Cre (10), and Jag1flox;Nkx2.5-Cre
(13).
RESULTS
MEEC Show Features of Embryonic Endocardium—To in-
vestigate the NOTCH-dependent endocardial secretome, we
used a previously generated MEEC line (10). Morphological
examination revealed a cobblestone-like morphology resem-
bling that of human umbilical vein endothelial cells, contrast-
ing the elongated shape of mouse embryonic fibroblasts (Fig.
S1A). MEEC showed positive staining with the endothelial
surface marker isolectin B4 (35) (Fig. S1B) and for immuno-
detected ERG in the nucleus (36) (Fig. S1C). The endocardial
marker NFATc1 was diffusely expressed in the cytoplasm
(Fig. S1D) and translocated to the nucleus after the addition of
a Ca2 ionophore (37) (Fig. S1E). We tested the angiogenic
behavior of VEGF pretreated MEEC in an endothelial tube
formation assay on reduced growth factor Matrigel (38). In
response to angiogenic stimulation for 6 h, MEEC aligned and
formed capillary-like structures within the Matrigel, and the
tube network was more extensive after a higher initial seeding
density (Figs. S1F and S1G). These results indicate that MEEC
retain properties of embryonic endocardial cells and are thus
an appropriate in vitro system in which to manipulate endo-
cardial NOTCH signaling.
Analysis of the NOTCH-dependent Endocardial Secre-
tome—To achieve ligand-specific NOTCH signaling activation
or inhibition, we stimulated MEEC with immobilized recombi-
nant DLL4 or JAG1 ligands (14) in the presence of DMSO
(vehicle) or the -secretase inhibitor RO4929097 (RO) (Fig.
1A). This allowed us to compare the ligand-specific NOTCH-
dependent secretome in activating and inhibitory conditions.
NOTCH activation and abrogation were confirmed by qRT-
PCR of the NOTCH target genes Hey1, Hey2, HeyL, and Nrarp
(39–41) (Figs. 1B and 1C).
Serum-free conditioned media from each experimental
condition was analyzed by protein digestion followed by mul-
tiplexed isobaric labeling and analysis by LC-MS/MS (Fig.
S2A, see “Experimental Procedures”), resulting in the identi-
fication of peptides from nonredundant proteins across all
experimental conditions (Fig. 1D and Table S1). Based on
features that are shared among secreted proteins, they were
filtered by stringent computational analysis to select those
likely to be exported by live cells as soluble proteins. A final
list of 875 candidate defined the endocardial secretome (Fig.
1D and Table S2). Principal component analysis of the secre-
tome response revealed a treatment-based separation into
three clusters: ligand-driven NOTCH activation, NOTCH inhi-
bition, and nonstimulation (control) (Fig. S2B). Treatment trip-
licates showed an overall superposition, and the only three
outliers were included in the following statistical analysis.
Altogether, we achieved a meaningful stimulation and inhi-
bition of NOTCH signaling in MEEC, allowing selection of
potentially secreted proteins representing the NOTCH-de-
pendent endocardial secretome.
NOTCH Signaling Regulates Growth Factors and Extracel-
lular-Matrix Component Secretion—To study the overall effect
of NOTCH activation in the endocardial secretome composi-
tion, we focused on the 690 secreted proteins (78.6% of the
total) identified after both JAG1- and DLL4-stimulation (Fig.
S2C and Table S3A). Within this group, we selected only
secreted proteins showing significant changes (p  0.05) after
global NOTCH activation or inhibition (Table S3B). To this end,
we compared NOTCH activation (DLL4- and JAG1-DMSO
combined) versus NOTCH inhibition (DLL4- and JAG1-RO
combined), and NOTCH activation versus control (DMSO) and
NOTCH inhibition combined (Figs. S3A and S3B). Proteins
showing differential secretion in at least one comparison were
selected (n  129). Hierarchical clustering of these common
proteins by secretion pattern yielded four major groups (Fig.
2A), corresponding to proteins hyposecreted or hyperse-
creted after NOTCH inhibition (clusters 1 and 4; Fig. 2A) and
to proteins hyposecreted or hypersecreted after NOTCH ac-
tivation (clusters 2 and 3; Fig. 2A).
To better understand the functions of these NOTCH-re-
sponsive proteins, we conducted GO enrichment analysis of
the two major secretome profiles, based on hypersecretion
(clusters 1 and 3; Fig. 2A) and hyposecretion (clusters 2 and 4;
Fig. 2A) during NOTCH activation. The analysis showed that
the first group (59 proteins) had significant overrepresentation
of ECM-remodeling and collagen-related terms, in which sev-
eral components of the ECM (TGF2, CTGF, FBLN2, FN1,
and a variety of collagens) and remodeling enzymes (lysyl-
oxidase -LOX- and metalloproteinase inhibitors -TIMP1 and
TIMP3–) were included (Fig. 2B and Table S5A). In contrast,
the second group (70 proteins) showed enrichment in
semaphorin signaling and protein modification terms, in-
cluding ubiquitin-conjugating enzymes (NEDD4, UBE2K, and
UBE2V1), aminopeptidases (NPEPPS, PEPD, XPNPEP1), and
metalloproteinases (ADAM10, ADAMTS5, AEBP1) (Fig. 2C
and Table S5A). Similar results were obtained with KEGG
pathway analysis, further supporting the notion that NOTCH
stimulation promotes the secretion of paracrine signals in-
volved in “ECM-receptor interaction,” “focal adhesion,”
“pathways in cancer,” and “TGF signaling,” which are
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closely associated with cellular migration and invasiveness
and with diminished secretion of guidance/chemotaxis sig-
nals, like semaphorins (Figs. 2B and 2C).
To identify the protein-protein interactions underlying the
functions described above, we constructed the interactome
of the NOTCH-dependent endocardial secretome by integrat-
FIG. 1. Profiling the endocardial-derived secretome through in vitro modulation of the NOTCH pathway in MEEC. (A) Experimental
design of MEEC proteome analysis. MEEC were stimulated with the recombinant NOTCH ligands DLL4-His10 (green) or JAG1-hIgG1Fc, in
combination with vehicle (DMSO) or the -secretase inhibitor RO4929097 (RO). At the end of the treatment period, cells were collected for
qRT-PCR analysis and protein content in conditioned media was analyzed by LC-MS/MS. (B, C) qRT-PCR analysis of canonical Notch target
genes Hey1, Hey2, HeyL, and Nrarp in DLL4-stimulated MEEC (B) and JAG1-stimulated MEEC (C). Data are means of triplicate measures of
each sample and are presented as mean  s.d. (Student’s t test; *p  0.05; **p  0.01, ***p  0.005). (D) Workflow of sequential bioinformatics
analysis with the DAVID, TMHMM, SignalP, and SecretomeP servers to identify secreted proteins. Circles show the number of proteins in each
group; orange indicates secreted proteins.
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ing the 129 differentially expressed proteins with the STRING
v11 database (26) (Table S6A). We predicted a statistically
significant network containing 78 nodes (39 hypersecreted
and 39 hyposecreted) connected by 229 edges representing
physical or functional interactions (Fig. 3A and Table S6B). We
identified two major clusters containing the most densely
connected nodes (enclosed by a dotted line in Fig. 3A) in
which 29 out of 39 nodes corresponded to hypersecreted
proteins. Among them, the most interconnected proteins were
structural proteins (collagens) and ECM-remodeling factors
(bold names in Fig. 3A). These proteins appeared in the most
represented GO terms and KEGG pathways, which corre-
sponded with extracellular matrix, collagen organization, re-
sponse to stimulus, ECM-receptor interactions, and focal ad-
hesion. The other nodes were mostly hyposecreted proteins
forming poorly interconnected networks. Interestingly, we
found an increase in RAB7 levels, a key regulator in the
endo-lysosomal trafficking, suggesting that NOTCH might
also mediate a cross-talk to the neighboring cells through the
release of signals that are packaged into vesicles (42).
Overall, our analysis indicated that NOTCH-mediated para-
crine signaling in the endocardial secretome modulated TGF
FIG. 2. Global NOTCH-associated secretory profile. (A) Hierarchical clustering of the 129 secreted factors displaying significant abun-
dance changes (t test, p  0.05) in comparisons of NOTCH activation versus inhibition or of NOTCH activation versus the combination of
control plus inhibition. Dashed lines mark the delineation of four clusters; yellow clusters (1, 3) show increased abundance upon NOTCH
activation; purple clusters (2, 4) show decreased abundance upon NOTCH activation. (B, C) Charts showing enrichment analysis for GO terms
and KEGG pathways for proteins hypersecreted (B) or hyposecreted (C) in response to NOTCH activation. Colored boxes show names of
secreted factors in each cluster pair.
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signaling, focal adhesion, and ECM formation to regulate
cellular movements during cardiac development.
DLL4 and JAG1 Ligands Determine a Distinct Secretome
Composition—During heart valve development, DLL4 and
JAG1 act sequentially to activate NOTCH signaling. Early
endocardial DLL4-NOTCH activity drives the EMT that will
lead to the formation of the valve primordium. Later on, JAG1-
NOTCH signaling is crucial for the regulation of valve mesen-
chyme cell proliferation (13). To determine whether DLL4 and
JAG1 elicit different protein secretion responses in MEEC, we
compared the secretomes obtained after stimulation with
JAG1 and DLL4, using the same statistical analysis as in the
previous section. JAG1-mediated stimulation altered the se-
cretion of 82 proteins, whereas DLL4 altered the secretion of
113 proteins (Fig. 4A and Tables S4A and S4B). Only 24
proteins were altered in both JAG1- and DLL4-stimulated
MEEC. Thus, 70–80% of the differentially secreted proteins
were ligand specific. To visualize the changes in protein abun-
dance, we performed a hierarchical clustering of the JAG1-
and the DLL4-dependent secretome (Figs. 4B–4D). Hyperse-
cretion (compared with the control and RO situations) was the
main effect in the JAG1-dependent secretome; in contrast,
with DLL4 stimulation, the main effect was hyposecretion.
Interestingly, most of the 24 secreted proteins altered in both
JAG1- and DLL4-stimulated MEEC responded similarly to
both ligands (clusters 1 and 3 in Fig. 4D and Table S4C).
To associate specific functions to each ligand, we focused
on those clusters showing major protein-level alterations after
ligand activation (dashed boxes in Figs. 4B and 4C). We
distinguished between proteins identified as hypersecreted
(yellow dashed box in Figs. 4B and 4C) and hyposecreted
(purple dashed box) in the JAG1- or the DLL4-specific secre-
tome. GO and KEGG pathway analysis of these clusters re-
vealed distinct biological functions associated with each li-
gand (Fig. 4E and Table S5B). Proteins whose secretion was
reduced after DLL4 activation (Fig. 4C) belonged to the GO
terms “glucose metabolic processes,” “cellular component
disassembly,” and “regulation of blood circulation,” whereas
FIG. 3. Interactome of NOTCH-asso-
ciated secretory profile. (A) NOTCH-
dependent interactome, showing 78
nodes (differentially secreted proteins in
at least one comparison: NOTCH activa-
tion versus inhibition, or NOTCH activa-
tion versus the combination of control
plus inhibition. The nodes are connected
by 229 edges (physical or functional in-
teractions). The purple-yellow gradient
of the edges reflects their degree of in-
teraction (from high to low). Dashed lines
delineate those nodes forming the most
densely connected clusters. Red and
blue indicate higher and lower secretion
upon NOTCH activation, respectively.
Bold names represent ECM-remodeling
proteins.
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hypersecreted proteins were related to “cell-cell junction or-
ganization” (DSP, JUP), “organelle organization,” or “cell de-
velopment” (TGF2). In contrast, the most enriched terms
among the JAG1-specific hypersecreted proteins (Fig. 4B)
were “platelet-derived growth factor binding,” “regulation of
cartilage and blood vessel development,” and “collagen fibril
organization” (collagens), whereas hyposecreted proteins
were involved in “semaphorin receptor binding” (sema-
phorins) (Fig. 4E and Table S5B). Thus, DLL4 seems to affect
the secretion of proteins playing a role in cellular metabolism,
cell adhesion, and cytoskeletal dynamics, whereas JAG1
leads to changes in ECM structure and semaphorins. These
results showed that stimulation with DLL4 and JAG1 triggered
different secretome responses in MEEC, likely reflecting the
different roles played by these ligands during heart valve
development.
NOTCH-driven Gene Expression Correlates with Protein
Secretion—To validate the secretome data, we examined
whether the protein secretion changes after NOTCH stimula-
tion or inhibition in MEEC were accompanied by similar
changes in mRNA expression. Thus, we analyzed the expres-
sion of NOTCH-responsive proteins representing the most
enriched GO categories by qRT-PCR (Fig. 5A). In the case of
genes encoding proteins hypersecreted when comparing
NOTCH activation versus NOTCH inhibition, we found that
JAG1 enhanced the transcription of Fn1, Tgf2, Col4a1, and
Ctgf, molecules related to ECM remodeling and EMT, as well
as the ECM-remodeling enzymes Timp1, Timp3, Mmp2, and
Loxl2, whereas DLL4 stimulation up-regulated Tgf2 and
Timp3 (Fig. 5A). In agreement with the secretome data (Fig.
5B), all these genes were downregulated in the presence of
RO (Fig. 5A). Opposite results were obtained for Sdc4, Ptx3,
Sema3a, and Sema3e, which were strongly up-regulated
upon NOTCH abrogation (Fig. 5A). Further, we compared the
secretome data with available transcriptomic data from MEEC
co-cultured for 24 h with DLL4- or JAG1-expressing OP9 cells
(Luna-Zurita, MS in preparation). The comparison distin-
guished between secreted proteins with significant differ-
ences at the transcript or protein level, at the protein level or
at both (Figs. S4A and S4B and Table S7A). Despite the
relatively poor correlation between secretion and expression
when comparing those significantly changed at least at one
level (r  0.2953 for JAG1 and r  0.1749 for DLL4), we found
a positive correlation when we focused on those proteins
differentially secreted and expressed after NOTCH pathway
activation (r  0.6965 for JAG1 and r  0.6685 for DLL4; Figs.
S4A and S4B and Table S7A). Some of the most functionally
relevant proteins identified in our secretome data were
among the proteins whose abundance changes were re-
flected at the transcript level (Tables S7B and S7C). This
was the case for the hypersecreted/up-regulated factors
TGF2, FN1, COL1A1, COL5A1, COL6A1, and COL6A2
and for the hyposecreted/downregulated factors SEMA3A,
SEMA3C, SEMA3D, SEMA3E, SDC4, and PTX3 (Fig. 5C and
Table S7D). These results showed a positive correlation be-
tween NOTCH-dependent protein secretion and mRNA expres-
sion levels and strongly suggest that NOTCH signaling alters
protein secretion through transcriptional regulation.
In Vivo Validation of NOTCH-dependent Endocardial
Secretome Candidates—During cardiac valve development,
NOTCH drives the EMT that gives rise to the valves primordia
(43) and later regulates mesenchyme proliferation and differ-
entiation to generate the adult valves (13, 44, 45). Both of
these processes require exquisite regulation of ECM produc-
tion and maturation.
Given the prominent contribution of ECM-related proteins
to the MEEC NOTCH-dependent secretome (Fig. 2B; Table
S5), we examined developing mouse valves for the transcript
expression of selected ECM-related molecules. Based on the
transcriptomic and proteomic responses to NOTCH activation
(Figs. 5A and 5B), we selected Tgf2, Loxl2, Ptx3, Timp3,
Fbln2, and Dcn for the in vivo validation. TGF2 is a member
of the TGF family that promotes endocardial cushion forma-
tion by EMT (46, 47). LOXL2 is an enzyme responsible for
covalent crosslinking of ECM components (48). PTX3 is a
cytokine involved in the conversion of mesenchyme cancer
cells into epithelium (49). TIMP3 is the major inhibitor of matrix
metalloproteinases (50). FBLN2 is a glycoprotein that plays a
central role in matrix stabilization (51). Finally, DCN is a pro-
teoglycan that interacts with collagens and free TGF to
provide a structural scaffold in connective tissues (52). ISH
revealed expression of these genes, with the exception of Dcn
(data not shown), in the outflow tract (OFT) and atrioventric-
ular canal (AVC) regions of the E10.5 mouse heart (Fig. S5A).
Consistent with a previous report (47), Tgf2 was expressed
in AVC and OFT endocardium and mesenchyme and in the
myocardium (Fig. S5A). However, Loxl2, Ptx3, Timp3, and
Fbln2 were confined to the endocardium and cushion mes-
enchyme (Fig. S5A). At E15.5, the AVC endocardial cushions
have given rise to the atrioventricular valves (mitral and tricus-
pid) and the OFT cushions to the semilunar valves (aortic and
pulmonary). Loxl2, Ptx3, Timp3, Fbln2, and Dcn were ex-
FIG. 4. DLL4 and JAG1 elicit distinct secretory profiles. (A) Venn diagram showing overlap of differentially secreted proteins (t test, p 
0.05) in at least one comparative analysis (NOTCH activation versus inhibition or NOTCH activation versus the combination of control plus
inhibition), with JAG1-specific and DLL4-specific signaling considered separately. (B–D) Heatmaps showing z-score-normalized fold changes
for proteins differentially secreted exclusively in response to signaling by JAG1 (B), DLL4 (C), or by both ligands (D), in at least one comparison.
In D, protein names are given alongside each row, and the dashed line distinguishes between three major clusters based on their secretory
behavior. (E) Heatmap showing the GO-Elite server-generated list of enriched GO terms and KEGG pathways for hypersecreted (yellow dashed
line in B and C) and hyposecreted proteins (purple dashed line) in response to stimulation with JAG1 (orange) and DLL4 (green) stimulation.
Color scale represents z-enrichment scores. Colored boxes show names of secreted factors in each cluster.
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pressed in the endocardium and mesenchyme of the atrio-
ventricular valves and OFT valves (Fig. S5B). These results
showed that the selected MEEC secretome genes are ex-
pressed in cardiac tissues undergoing developmental pro-
cesses in which the ECM plays a crucial role, such as valve
morphogenesis.
We next assessed whether NOTCH pathway inactivation in
vivo triggered the same gene expression changes observed in
MEEC. At E9.5, DLL4 is essential for EMT and endocardial
cushion formation in the AVC (13). We conditionally inacti-
vated Dll4 in the developing endothelium and endocardium by
crossing mice bearing a conditional Dll4flox allele (33) with the
driver line Tie2-Cre (31). Whole-mount ISH analysis of E9.5
Dll4flox;Tie2-Cre mutant hearts revealed a severely reduced
expression of Tgf2 in the AVC region (endocardium and
myocardium) (Figs. 6A and 6B), of Loxl2 in the AVC endocar-
dium (Figs. 6C and 6D), and of Fbln2 in the AVC endocardium
and mesenchyme (Figs. 6E and 6F). In contrast, expression of
Ptx3, Dcn, and Timp3 was unaffected (data not shown). These
findings are consistent with reports indicating that Tgf2 is a
NOTCH target during early valve development (4) and identify
Fbln2 and Loxl2 as potential novel EMT mediators down-
stream of NOTCH. JAG1 regulates mesenchyme proliferation
and differentiation during valve morphogenesis (13). To ablate
Jag1 throughout the myocardium and endocardium and its
mesenchymal derivatives, leading to valve dysmorphology
(13), we bred Jag1flox mice (34) with the cardiac-specific
Nkx2.5-Cre driver line (32). ISH analysis revealed that in-
creased valve cellularity of Jag1flox;Nkx2.5-Cre mutant em-
bryos at E14.5 was accompanied by altered expression of
Loxl2 (Figs. 6G–6H	), Fbln2 (Figs. 6I–6J	), and Ptx3 (Figs.
6K–6L	). However, Tgf2, Timp3, and Dcn remained un-
changed (data not shown). In agreement with the secretome
data (Fig. 4D and Table S4C), Loxl2 and Fbln2 mRNA were
reduced in Jag1flox;Nkx2.5-Cre mutant valves (Figs. 6G–6J	),
whereas Ptx3 was up-regulated (Figs. 6K–6L	). This finding is
FIG. 5. mRNA-level validation of
candidate NOTCH-regulated secreted
factors. (A) MEEC endogenous expres-
sion of candidate NOTCH-responsive ef-
fectors selected for validation by qRT-
PCR: Fn1, Tgf2, Timp1, Timp3, Loxl2,
Ctgf, Col4a1, Mmp2, Sema3e, Sdc4,
Ptx3, and Sema3a. Data are means of
triplicate measures for each sample and
are presented as mean  s.d. (Student’s
t test *p  0.05; **p  0.01, ***p 
0.005). (B) Heatmap showing mean z-
score-normalized fold changes for differ-
entially secreted proteins selected for
gene expression analysis. The dashed
line distinguishes between two major
clusters based on their secretory behav-
ior. (C) Cartoon depicting MEEC-derived
proteins whose transcript levels (meas-
ured by RNA-Seq analysis) reflect the
same protein abundance variations
found in the secretome, with JAG1-
and DLL4-specific signaling consid-
ered separately. UP refers to “up-regu-
lated” and DOWN to “downregulated”
during NOTCH activation.
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consistent with the secretome data (Table S4) and suggests
a positive correlation between increased Ptx3 transcription
and the presence of excessive immature mesenchyme after
JAG1-NOTCH signaling blockade (13). In summary, our results
validate MEEC as a powerful in vitro model of endocardial cell
signaling and support the potential of this in vitro system to
identify molecules involved in valve morphogenesis.
DISCUSSION
We have generated an in vitro system to circumvent the
severe limitation imposed on proteomic studies of early heart
development by the tiny amounts of cardiac tissue available.
Using MEEC, we have been able to identify for the first time
the NOTCH-dependent embryonic endocardial secretome.
MEEC have cellular and functional features of endothelium
(Isolectin B4 staining and ERG expression), showing a cob-
blestone appearance and an ability to form capillary-like
structures in Matrigel. In addition, MEEC express a typical
endocardial marker (NFATc1), demonstrating that they are a
suitable in vitro experimental system in which to assay the
effect of NOTCH-signaling manipulation on protein secretion,
as well as for future investigation into endocardial cell biology.
We stimulated MEEC with the recombinant ligands DLL4 or
JAG1, demonstrating NOTCH pathway activation and its in-
hibition in the presence of RO and examining target-gene
expression by qRT-PCR in these settings. Quantitative pro-
teomics analysis of conditioned media from the different ex-
perimental conditions identified proteins whose secretion re-
sponds to NOTCH manipulation. To analyze the proteome
data, we combined advanced quantitative statistical models
FIG. 6. In vivo validation of Tgf2,
Loxl2, Fbln2, and Ptx3 as NOTCH-tar-
get genes in NOTCH pathway mouse
mutants. (A–F) Whole-mount ISH analy-
sis in E9.5 WT and Dll4flox;Tie2-Cre em-
bryos, showing a general view of the
heart. Tgf2 expression in AVC myocar-
dium (A) is lost in mutants (B, asterisk).
Loxl2 expression in AVC endocardium
(C, arrowheads) is decreased in mutants
(D, asterisk). Fbln2 expression in AVC
endocardial and mesenchymal cells (E,
arrowheads) is markedly downregulated
in mutants (F, asterisk). (G–L	) ISH anal-
ysis in heart sections from E14.5 WT and
Jag1flox;Nkx2.5-Cre embryos. Expres-
sion of Loxl2 (G–H	) and Fbln2 (I–J	) is
lower in endocardial and mesenchymal
cells of mutant atrioventricular valves,
whereas Ptx3 is up-regulated in mesen-
chymal cells (K–L	). Boxed areas are
magnified in the panels on the right
(
 tricuspid valve; 	 mitral valve). Scale
bars: 100 m. a (atria), avc (atrioventric-
ular canal), ivs (interventricular septum),
lv (left ventricle), mv (mitral valve), tv
(tricuspid valve).
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(15, 17, 18) with various web-based interfaces, identifying 875
secreted factors, 129 of which underwent significant expression
changes upon NOTCH manipulation. NOTCH activation corre-
lated directly with an increased secretion of ECM remodeling
and structural proteins (TGF2, collagens) and inversely with
guidance signals (semaphorins) and protein-modifying en-
zymes. These results are consistent with the reported relation-
ship in cardiovascular development between NOTCH, ECM
dynamics, and semaphorins in cardiovascular development (53,
54) and indicate an additional level of regulation through protein
secretion. The identified secretome profiles were ligand spe-
cific. DLL4-NOTCH signaling mostly stimulated the production
of TGF2, intercellular junction proteins, and cytoskeletal pro-
teins, suggesting an involvement in EMT, cell-cell/cell-matrix
adhesion and cytoskeleton signaling. In contrast, JAG1-NOTCH
signaling prompted higher levels of collagen-related proteins,
indicating a major contribution to EMT and ECM deposition.
These findings agree with the early role described for DLL4-
NOTCH1 signaling in the promotion of EMT and cell migration
versus the later role of JAG1-NOTCH1 in the regulation of valve
mesenchyme proliferation and remodelling (13).
qRT-PCR validation of selected differentially secreted pro-
teins identified in the MEEC secretome experiments revealed
a marked correspondence between mRNA and protein secre-
tion dynamics. This correlation between mRNA and protein
secretion dynamics was confirmed by analysis of RNA-Seq
data from DLL4- and JAG1-stimulated MEEC, strongly sug-
gesting that protein delivery is influenced by a NOTCH-
dependent transcriptional regulation. Participation of the
NOTCH secretome in EMT and ECM dynamics was further
validated by in vivo analysis of selected potential NOTCH-
responsive genes (Tgf2, Loxl2, Ptx3, Timp3, Fbln2, and Dcn)
expressed in the early (E10.5) and remodeling (E15.5) heart
valve. Interestingly, Tgf2 was previously described as a se-
creted NOTCH effector (4) mediating EMT initiation (55). The
detection of this cytokine in the MEEC secretome thus not
only highlights the sensitivity of our approach, but also indi-
cates the appropriateness on the proteome dataset for ex-
ploring the EMT signaling cascade downstream of NOTCH. At
early stages, Loxl2, Ptx3, Timp3, and Fbln2 were restricted to
endocardium and mesenchyme cells configuring the AVC
cushions and the OFT, whereas Tgf2 was also present in the
myocardium of both territories, in agreement with previous
publications (56). Later in development, Dcn and the remain-
ing candidates were also expressed in the atrioventricular and
semilunar valve leaflets. These results suggest that these
factors contribute to valve development and may play distinct
roles according to their differential spatio-temporal localiza-
tion in the endocardium and mesenchyme. The relationship
between NOTCH signaling and these paracrine factors was
confirmed by analyzing their expression in Dll4 and Jag1
targeted mutants. Tgf2, Loxl2, and Fbln2 transcripts were
downregulated in E9.5 Dll4flox;Tie2-Cre mutant hearts, in
which EMT is impaired (13). A similar reduction in Tgf2
expression was previously reported in RBPJ and Notch1
mutants (43). These findings suggest that NOTCH1 activity
may trigger the transcription and subsequent release of Loxl2
and Fbln2 signals from the endocardium to initiate and sustain
EMT. Moreover, Loxl2 and Fbln2 expression was reduced and
Ptx3 expression increased in the atrioventricular valves of
E14.5 Jag1flox;Nkx2.5-Cre mouse mutants, which show hy-
perplastic valves and defective remodeling (13). These gene
expression changes paralleled those observed in the secre-
tome and suggest that imbalanced ECM molecule expression
may underlie impaired valve organization and remodeling.
We have thus identified three potential secretome markers
by which NOTCH might contribute noncell autonomously to
EMT: LOXL2, FBLN2, and PTX3. LOXL2 is a member of the
lysyl oxidase family, which plays a major role in ECM remod-
eling through the crosslinking of collagens and elastin (57) and
is involved in the posttranslational regulation of the EMT driver
SNAIL (58). FBLN2 is a matrix glycoprotein that plays a central
role in matrix stabilization, functioning as an intermolecular
clasp and facilitating supra-molecular assembly of collagen
IV, fibronectin, and other ECM molecules (59). In the heart,
FBLN2 is produced by the endocardial cushion tissue (60) and
has been suggested to maintain the mechanical properties of
the heart valves (61). PTX3 is a member of the pentraxin family
involved in the control of tumor development, affecting cell
proliferation and EMT in human melanoma cells in vitro (49).
hPTX3 overexpression causes the down-regulation of the
early mesenchymal markers SNAIL1 and SNAIL2, paralleled
by E-CADHERIN up-regulation, indicating that PTX3 overex-
pression inhibits EMT in melanoma cells by reversing their
mesenchyme phenotype to an epithelial one (49). Remark-
ably, PTX3 is the secreted factor that exhibited the most
restricted localization to the cardiac cushions and valves.
In summary, our results validate MEEC as a powerful in vitro
model for the study of the endocardial secretome. Manipula-
tion of NOTCH signaling has revealed the DLL4- and JAG1-
induced secretomes, and identified several secreted factors
whose transcripts are expressed during cushion formation
and valve remodeling and are altered in NOTCH mutant mice.
Functional analysis of these factors will provide insight into
how these signals are coordinated and how their disruption
might contribute to congenital valve defects and disease.
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